Equal emphasis is placed on therapeutic advances and preventive strategies, including vaccination and public health interventions. In addition, the book explores transformative innovations such as artificial intelligence in drug discovery, gene and stem cell therapies, transplantation medicine, and next-generation imaging. External forces shaping healthcare-climate change, armed conflict, pandemics, economic constraints, and recent political developments, including the impact of US health research policies-are critically assessed.
Table of Contents
Part I. Healthcare in global epidemiological terms1. Introduction
2. Methodology
3. Global demographics Population dynamics Forecasts till 2100
4. Selection of fifty-two countries for analysis of their demographic parameters
5. Key human development parameters
6. Evolution of poverty in developing countries
7. Top ten causes of death and disability combined
8. Expenditure for healthcare in fifty-two countries; role of external funding
Part II. Major Disease Groups
9. Global chart of non-communicable and communicable diseases
10. Cardiovascular diseases
11. Cancer
12. Infectious diseases, Pandemics & Neglected Tropical Diseases
13. Neurodegenerative diseases/Dementia
14. Malnutrition and obesity
15. Rare diseases
Part III. Novel Technologies
16. AI in drug discovery and development
17. Recent breakthroughs in gehe therapy
18. Vaccines
19. Stem Cell Therapies
Part IV. External Factors Impacting Healthcare
20. Economic aspects Access to Health Services; Availability and Affordability of essential medicines in developing countries
21. Cuba and Singapore two interesting case studies
22. Impact of climate change
23. Wars and armed conflicts
24. Healthcare and the UN Sustainable Development Goals (SDG)
Authors
Alex Matter Senior Fellow, A*STAR, Singapore.Dr. Matter is currently an Adjunct Professor of the Duke-NUS university in Singapore (Dept. Emerging Infectious Diseases) and a Senior Fellow of A*STAR, Singapore. He was CEO of the Experimental Therapeutics Centre from 2009 until 2018; from 2012 to 2018 he was also the CEO of a newly created Drug Discovery & Development platform, A*STAR, Singapore. This platform developed two anti-cancer compounds to Phase 1B clinical trials. Previously, he spent five and a half years (2003 - 2009) as Director of the Novartis Institute for Tropical Diseases (NITD). In this role, he started an international malaria research program that brought two compounds based on entirely novel principles to Phase II/III clinical trials. Prior to this role, he was Global Head of Oncology Research for Novartis Pharmaceuticals Corporation. Dr. Matter also built and led teams successful in discovery and development of several anticancer drugs, as well as one HIV protease inhibitor.
